The Science of the “Reset”: How Ketamine Addresses Suicidal Ideation

Suicidal ideation — thoughts of ending one’s life — is one of the most urgent and least adequately addressed symptoms in psychiatric medicine. Standard antidepressants can take four to six weeks to produce any measurable effect, a timeline that offers little protection during a crisis. Research has shown that ketamine may reduce suicidal ideation within hours, through mechanisms that do not depend on the slow neurochemical changes that define conventional treatment (NIMH, 2014).

This blog is educational and intended for patients, families, and referring providers who want to understand the science behind ketamine’s effect on suicidal thinking. If you or someone you know is in immediate crisis, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room before reading further.

Understanding Suicidal Ideation as a Symptom

Suicidal ideation is not a separate diagnosis — it is a symptom that occurs most commonly in the context of major depressive disorder, PTSD, bipolar disorder, and other mood conditions. It exists on a spectrum, from passive thoughts that life is not worth living to active planning and intent. Across that spectrum, it is a clinical signal that the underlying condition is severe and that standard treatment may not be working adequately.

For patients with treatment-resistant conditions, suicidal ideation is particularly common and particularly difficult to manage. The medications that are typically first-line for depression — SSRIs and SNRIs — were not designed with rapid crisis intervention in mind. They address the neurochemistry of chronic mood dysregulation over weeks. When a patient is acutely struggling with thoughts of self-harm, weeks is a clinically meaningful gap.

At Thrive Center for Health, suicidal ideation is listed among the conditions we treat through IV ketamine therapy — not as a standalone diagnosis, but as a symptom that may respond rapidly to ketamine’s unique mechanism of action when it occurs in the context of a mood disorder or other qualifying condition.

The Neuroscience: Why Ketamine May Act So Quickly

To understand why ketamine may help with suicidal ideation faster than conventional treatments, it helps to understand what is happening in the brain during severe depression.

The prefrontal cortex — the region of the brain responsible for executive function, emotional regulation, and decision-making — shows reduced activity and impaired connectivity in people with severe depression. This dysregulation contributes to the cognitive distortions, hopelessness, and inability to envision the future that characterize both depression and suicidal thinking. Standard antidepressants address this partly through monoamine systems (serotonin and norepinephrine), but the process is slow and indirect.

Ketamine works differently. It blocks NMDA receptors — a class of glutamate receptors — which triggers a rapid cascade of neurological events in the prefrontal cortex (Zanos & Gould, 2018). This includes the promotion of neuroplasticity: the brain’s ability to form new neural connections, strengthen existing pathways, and repair cellular damage (Deyama & Bhatt, 2021). To better understand exactly what this looks like inside the brain, our post on how ketamine affects the brain offers a detailed walkthrough. In practical terms, this may help the brain rapidly rebuild the connectivity and functional capacity that depression has eroded.

The NIMH has documented that ketamine restores pleasure-seeking behavior — anhedonia, the inability to feel pleasure, is a core feature of severe depression — ahead of other antidepressant effects (NIMH, 2014). Clinically, this matters. The disappearance of harmful thoughts, including suicidal ideation, is often among the first changes patients and our team notice following a ketamine infusion. This is consistent with what the research literature describes: a rapid shift in the symptom clusters most directly tied to risk.

What the “Reset” Means Clinically

The phrase “reset” is not a scientific term, but it reflects something patients often describe after a ketamine infusion — a sense that the relentless, circular quality of their negative thinking has quieted. This is not simply sedation or euphoria. During the infusion, patients are awake and monitored throughout. Some enter a meditative state; some experience heightened sensory awareness. The therapeutic effect is not the experience itself — it is the neurological shift that occurs as a result.

Harmful thoughts such as suicidal ideation, harm to self, and harm to others are often the first symptoms to diminish following treatment. This aligns with the neurobiological explanation — rapid glutamate system modulation affects the cognitive and emotional processes most tightly linked to acute risk before it achieves the broader mood stabilization that takes longer to consolidate. For a deeper look at what patients encounter session by session, see our overview of the ketamine infusion therapy patient experience.

Ketamine therapy is not a standalone crisis intervention, and we do not present it as a substitute for emergency psychiatric care. Patients experiencing acute suicidal crisis should access emergency services first. What ketamine may offer — within the structure of a supervised clinical setting, following appropriate screening — is a meaningful reduction in the severity and persistence of suicidal ideation for patients with treatment-resistant conditions, at a speed no currently available oral antidepressant can approach.

Our Clinical Process for This Patient Population

Every patient who comes to Thrive Center for Health for ketamine therapy — including those presenting with suicidal ideation — completes both a psychiatric clearance and a medical clearance before any infusion begins. This is not a formality. It is how we determine whether ketamine is clinically appropriate for each individual, establish a baseline, and build a treatment plan that addresses the full picture.

Our providers — including board-certified Psychiatric Mental Health Nurse Practitioners Erika (DNP, ANCC board-certified, ASKP3-trained, 11+ years clinical experience) and Kari (PMHNP, ASKP3-trained) — are trained specifically in ketamine-assisted care. Medical Director Dr. Drumm, a General Psychiatrist, brings specific clinical interest in treatment-resistant depression and PTSD, the two conditions most commonly associated with persistent suicidal ideation in the patients we see.

Patients in the initial series receive 6–10 infusions. Sessions run approximately one to one and a half hours each, including recovery time. We monitor vital signs continuously throughout the infusion and remain present until it is safe for you to leave. You will need a ride home — you cannot drive on the day of treatment.

Addressing the Fear of Seeking Care

We hear, often, from patients who have delayed seeking treatment for suicidal ideation because they are afraid of what happens when they disclose it to a provider. They worry about involuntary hospitalization, about losing control of their care, or about being labeled in ways that follow them. These fears are understandable, and they are a genuine barrier to care that we want to address directly.

At our clinic, disclosure of suicidal ideation is part of the clinical picture we are here to assess and treat — not a trigger for automatic escalation. The clearance process is a collaborative evaluation, not an interrogation. Our team’s goal is to understand what you are experiencing so we can determine the right treatment approach. We encourage you to bring your full history, including any history of suicidal thinking, to your consultation. That information helps us help you.

Cost is another real barrier. Without accepted insurance, the initial psych clearance is $250 and each infusion in the mental health protocol is $500. For patients with accepted insurance — including Cigna, BCBS, Priority Health, Aetna, McLaren, Molina, TriCare, Michigan Medicaid, and Michigan Medicare — the cash portion per infusion drops to $300, with the consult billed to insurance. Veterans receive a 10% discount on all visits. If cost is a concern, review our comprehensive health insurance information or contact our team before scheduling to discuss your coverage and options.

Frequently Asked Questions

Can ketamine therapy be used specifically for suicidal ideation? At our clinic, suicidal ideation is treated as a symptom associated with mood disorders and other qualifying conditions — not as an isolated diagnosis. Ketamine therapy may help reduce suicidal thinking rapidly in the context of treatment-resistant depression, PTSD, bipolar disorder, or OCD. Candidacy is determined through our screening process. If you are in active crisis, please contact emergency services first.

How quickly might suicidal thoughts decrease after a ketamine infusion? Research and clinical observation both suggest that harmful thoughts — including suicidal ideation — may be among the first symptoms to diminish following a ketamine infusion, sometimes within hours. However, results vary by individual, and not every patient will respond in the same way or on the same timeline. Our team monitors your response closely across sessions.

Is it safe to tell my Thrive provider that I have thoughts of suicide? Yes. Disclosing suicidal ideation is part of the clinical evaluation process, and our team is trained to receive that information as a clinical symptom rather than an automatic trigger for hospitalization. We encourage full transparency during the consultation — it directly informs the treatment plan. If you are in immediate danger, call or text 988 or go to your nearest emergency room.

What if ketamine does not reduce my suicidal thinking? Results vary by individual, and ketamine is not effective for everyone. If the initial series does not produce the expected response, our team will discuss what that means for your treatment plan and what other options may be available. We do not discontinue care simply because a first approach did not work as hoped.

Does ketamine treat the underlying condition or just the symptoms? The research suggests ketamine does both simultaneously — it promotes neuroplasticity and rebuilds neural connectivity in ways that address the underlying biology of depression and related conditions, not just surface-level symptom suppression (Deyama & Bhatt, 2021). The rapid reduction in suicidal ideation may reflect the first phase of a deeper neurological shift that consolidates over the course of the initial series.

Key Takeaways

• Suicidal ideation is a symptom associated with treatment-resistant depression, PTSD, bipolar disorder, and OCD — conditions for which IV ketamine has a clinical evidence base and which Thrive Center for Health treats directly.
• Ketamine works through NMDA receptor blockade in the glutamate system, producing rapid neuroplastic changes in the prefrontal cortex that may reduce harmful thoughts within hours of an infusion.
• Harmful thoughts, including suicidal ideation, are often the first symptoms to diminish following ketamine treatment — a pattern consistent with the speed and mechanism of the drug’s action.
• The clinical process at Thrive includes psychiatric and medical clearance before any infusion, continuous monitoring during sessions, and an initial series of 6–10 infusions with maintenance available as needed.
• Seeking care for suicidal ideation does not automatically result in hospitalization — disclosing your full history during the evaluation helps our team build the most appropriate treatment plan for your situation.

If you or someone you care about has been living with suicidal ideation alongside a treatment-resistant mood condition, and standard care has not provided adequate relief, we want to have an honest conversation about what IV ketamine therapy may offer. Call Thrive Center for Health at 616-730-8069 or schedule a consultation with our team. Our providers will review your history, explain your options clearly, and help you decide whether this approach is right for your situation. Results vary by individual — we will tell you what we know, and we will tell you what we do not.

References

Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/

Deyama, S., & Bhatt, S. (2021). Ketamine and neuroplasticity: Rapid antidepressant mechanisms. Frontiers in Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/

National Institute of Mental Health. (2014). Rapid agent restores pleasure-seeking ahead of other antidepressant action. https://www.nimh.nih.gov/news/science-updates/2014/rapid-agent-restores-pleasure-seeking-ahead-of-other-antidepressant-action

Medical Disclaimer

The information in this blog is provided for educational purposes only and does not constitute medical advice. Ketamine therapy for suicidal ideation and related mood conditions should only be pursued under the supervision of a licensed medical provider familiar with your full psychiatric and medical history. Individual results vary — not every patient will respond to ketamine therapy, and no specific outcome can be guaranteed. This content is not a substitute for emergency psychiatric care. If you are experiencing suicidal thoughts or a mental health crisis, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room immediately. Discuss all treatment options with a qualified healthcare provider before making decisions about your care.